Literature DB >> 14749657

Outcomes after expectant management of extremely preterm premature rupture of the membranes.

Mara J Dinsmoor1, Rebecca Bachman, Elaine I Haney, Marci Goldstein, William Mackendrick.   

Abstract

OBJECTIVE: This study was undertaken to assess contemporary outcomes in pregnancies managed expectantly after extremely preterm premature (< or =24 weeks) premature rupture of the membranes (EPPROM). STUDY
DESIGN: We queried antepartum and ultrasound databases for patients with EPPROM. Data on pregnancy outcome and short-term neonatal outcomes were collected.
RESULTS: Forty-six patients with EPPROM were studied. Patients were hospitalized at 24 weeks' gestation and given antibiotics and antenatal steroids. Median gestational age at PPROM was 22.0 weeks (range 16.9-24 weeks); 43 (93%) elected expectant management, 2 of whom later had an intrauterine fetal death. Median latency period to delivery was 13 days (range 0-96 days), with mean gestational age at delivery of 25.8+/-3.4 weeks. Overall survival was 47% (27 of 57 infants), after a median hospital stay of 71 days (range 17-209 days). Ten (37%) of the survivors have serious sequelae.
CONCLUSION: Although significant pregnancy prolongation after previable PPROM occurs in many cases, neonatal outcomes remain poor.

Entities:  

Mesh:

Year:  2004        PMID: 14749657     DOI: 10.1016/s0002-9378(03)00926-8

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  9 in total

1.  Fetal MRI for prediction of neonatal mortality following preterm premature rupture of the fetal membranes.

Authors:  Agnes Messerschmidt; Anna Pataraia; Hanns Helmer; Gregor Kasprian; Alexandra Sauer; Peter C Brugger; Arnold Pollak; Michael Weber; Daniela Prayer
Journal:  Pediatr Radiol       Date:  2011-09-10

2.  Offering induction of labor for 22-week premature rupture of membranes: a survey of obstetricians.

Authors:  F McKenzie; B Tucker Edmonds
Journal:  J Perinatol       Date:  2015-04-30       Impact factor: 2.521

3.  Vaginal Ureaplasma species increase chorioamnionitis in very preterm infants with preterm premature rupture of the membranes at < 28 weeks of gestation.

Authors:  Yu Suzuki; Kenji Horie; Yukari Yada; Yumi Kono; Chikako Hirashima; Rie Usui; Shigeki Matsubara; Akihide Ohkuchi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-09-22       Impact factor: 3.267

4.  Factors Associated with Previable Delivery following Second Trimester Rupture of Membranes.

Authors:  Alexis Panzer; Sarah Dotters-Katz; Marcela Smid; Kim Boggess; Tracy Manuck
Journal:  Am J Perinatol       Date:  2018-11-02       Impact factor: 1.862

5.  Prophylactic Antibiotics in Twin Pregnancies Complicated by Previable Preterm Premature Rupture of Membranes.

Authors:  Olivia Myrick; Sarah Dotters-Katz; Matthew Grace; Tracy Manuck; Kim Boggess; William Goodnight
Journal:  AJP Rep       Date:  2016-07

6.  Outcome at Two Years of Very Preterm Infants Born after Rupture of Membranes before Viability.

Authors:  Amelie Kieffer; Gaelle Pinto Cardoso; Caroline Thill; Eric Verspyck; Stéphane Marret
Journal:  PLoS One       Date:  2016-11-09       Impact factor: 3.240

7.  Prognosis of preterm premature rupture of membranes between 20 and 24 weeks of gestation: A retrospective cohort study.

Authors:  Sumire Sorano; Mayumi Fukuoka; Kaori Kawakami; Yoshihito Momohara
Journal:  Eur J Obstet Gynecol Reprod Biol X       Date:  2019-11-15

Review 8.  Economical Analysis of Different Clinical Approaches in Pre-Viability Amniorrhexis-A Case Series.

Authors:  Samuel Engemise; Fiona Thompson; William Davies
Journal:  J Clin Med       Date:  2014-01-09       Impact factor: 4.241

9.  Neonatal and maternal outcomes following midtrimester preterm premature rupture of the membranes: a retrospective cohort study.

Authors:  Laura Aoife Linehan; Jennifer Walsh; Aoife Morris; Louise Kenny; Keelin O'Donoghue; Eugene Dempsey; Noirin Russell
Journal:  BMC Pregnancy Childbirth       Date:  2016-01-29       Impact factor: 3.007

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.